AbbVie: Humira Continues To Be Attacked
Kirin Biologics brought a lawsuit to the UK High Court of Justice seeking a judgment against AbbVie and its dosing protocols. Shares of AbbVie move as its blockbuster Humira moves because the product accounts for roughly 60% of sales.
from Biotech News
0 Comments